Windward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.